Can maitake MD-fraction aid cancer patients?
MD组分对肿瘤患者的治疗有何作用？
【Alternative Medicine Review 交替医学评论】, June, 2002
by Noriko Kodama, Kiyoshi Komuta, Hiroaki Nanba 难波宏彰
Abstract
Maitake mushroom (Grifola frondosa) MD-fraction containing beta-1,6 glucan with beta-1,3 branched chains has previously exhibited strong anticancer activity by increasing immune-competent cell activity. (1,2) In this non-random case series, a combination of MD-fraction and whole maitake powder was investigated to determine its effectiveness for 22- to 57-year-old cancer patients in stages II-IV. Cancer regression or significant symptom improvement was observed in 58.3 percent of liver cancer patients, 68.8 percent of breast cancer patients, and 62.5 percent of lung cancer patients. The trial found a less than 10-20 percent improvement for leukemia, stomach cancer, and brain cancer patients. Furthermore, when maitake was taken in addition to chemotherapy, immune-competent cell activities were enhanced 1.2-1.4 times, compared with chemotherapy alone. Animal studies have supported the use of maitake MD-fraction for cancer.
摘要
灰树花多糖的MD组分主要是由含有beta-1，3糖苷键的beta-1，6葡聚糖组成，通过增强免疫细胞活性而显示其极强的抗肿瘤作用。在以下这组实验中，给一些年龄在22到57岁，临床分期在Ⅱ到Ⅳ期的肿瘤患者搭配服用MD组分和灰树花粉，来测定其对肿瘤治疗的效果。肿瘤消失或者明显的症状改善百分比在肝癌患者中达到58.3%，在乳腺癌患者中达到68.8，而在肺癌患者中则为62.5%。实验还发现灰树花对于白血病、胃癌和脑癌的治疗也有10% --20%的促进作用。另外，实验还发现，同单独化疗治疗相比，口服灰树花结合放化疗可以将免疫细胞的活性提高1.2-1.4倍，这些动物实验的结果验证了灰树花MD组分可以用于肿瘤的治疗。
Introduction
Prior to 1980, maitake mushroom was foraged but could not be cultivated in medium. Since 1981, however, this mushroom has been commercially cultivated in Japan and elsewhere. Cultivation and development of standardized products, such as the MD-fraction, have provided opportunities to study its various medicinal properties: antitumor, (1-5) antidiabetic, (6) antihyperlipoid, (7) and antihepatitis. (8) There is a growing consensus that maitake MD-fraction strongly enhances immune-competent cell activities.
介绍
在1980年以前，灰树花虽然被广泛种植，但是还没有在培养基中培养成功。直到1981年，灰树花在日本和世界各地广泛种植。灰树花的一些标准产品（如MD组分）的生产和开发为人们研究它的药用价值提供了方便，人们逐渐发现了其抗肿瘤、治疗糖尿病、高血压和高血脂的作用。灰树花增强免疫细胞活性的作用越来越被人们所认同。
Animal Studies
C3H mice bearing MM-46 carcinoma (breast tumor) were given either 0.5 mg/kg MD-fraction by intraperitoneal (i.p.) injection or 1.0 mg/kg MD-fraction by oral administration for 10 days. After day 20, solid tumors were extirpated and weighed to determine the tumor growth inhibition ratio. Tumor regression of 75-85-percent was observed. Treatment with the MD-fraction increased the activities of natural killer cells, cytotoxic T cells, macrophages, and delayed-type hypersensitivity T cells by 1.23-2.5 times. The production of interleukin-1 (IL-1) from macrophages and of interleukin-2 (IL-2) from helper T cells was potentiated by 1.7-3.4 times. From these results the conclusion may be drawn that the immune-competent cell abilities to inhibit tumor growth were enhanced by MD-fraction. (1,2)
MD组分对肿瘤患者的治疗有何作用？
【Alternative Medicine Review 交替医学评论】, June, 2002
by Noriko Kodama, Kiyoshi Komuta, Hiroaki Nanba 难波宏彰
Abstract
Maitake mushroom (Grifola frondosa) MD-fraction containing beta-1,6 glucan with beta-1,3 branched chains has previously exhibited strong anticancer activity by increasing immune-competent cell activity. (1,2) In this non-random case series, a combination of MD-fraction and whole maitake powder was investigated to determine its effectiveness for 22- to 57-year-old cancer patients in stages II-IV. Cancer regression or significant symptom improvement was observed in 58.3 percent of liver cancer patients, 68.8 percent of breast cancer patients, and 62.5 percent of lung cancer patients. The trial found a less than 10-20 percent improvement for leukemia, stomach cancer, and brain cancer patients. Furthermore, when maitake was taken in addition to chemotherapy, immune-competent cell activities were enhanced 1.2-1.4 times, compared with chemotherapy alone. Animal studies have supported the use of maitake MD-fraction for cancer.
摘要
灰树花多糖的MD组分主要是由含有beta-1，3糖苷键的beta-1，6葡聚糖组成，通过增强免疫细胞活性而显示其极强的抗肿瘤作用。在以下这组实验中，给一些年龄在22到57岁，临床分期在Ⅱ到Ⅳ期的肿瘤患者搭配服用MD组分和灰树花粉，来测定其对肿瘤治疗的效果。肿瘤消失或者明显的症状改善百分比在肝癌患者中达到58.3%，在乳腺癌患者中达到68.8，而在肺癌患者中则为62.5%。实验还发现灰树花对于白血病、胃癌和脑癌的治疗也有10% --20%的促进作用。另外，实验还发现，同单独化疗治疗相比，口服灰树花结合放化疗可以将免疫细胞的活性提高1.2-1.4倍，这些动物实验的结果验证了灰树花MD组分可以用于肿瘤的治疗。
Introduction
Prior to 1980, maitake mushroom was foraged but could not be cultivated in medium. Since 1981, however, this mushroom has been commercially cultivated in Japan and elsewhere. Cultivation and development of standardized products, such as the MD-fraction, have provided opportunities to study its various medicinal properties: antitumor, (1-5) antidiabetic, (6) antihyperlipoid, (7) and antihepatitis. (8) There is a growing consensus that maitake MD-fraction strongly enhances immune-competent cell activities.
介绍
在1980年以前，灰树花虽然被广泛种植，但是还没有在培养基中培养成功。直到1981年，灰树花在日本和世界各地广泛种植。灰树花的一些标准产品（如MD组分）的生产和开发为人们研究它的药用价值提供了方便，人们逐渐发现了其抗肿瘤、治疗糖尿病、高血压和高血脂的作用。灰树花增强免疫细胞活性的作用越来越被人们所认同。
Animal Studies
C3H mice bearing MM-46 carcinoma (breast tumor) were given either 0.5 mg/kg MD-fraction by intraperitoneal (i.p.) injection or 1.0 mg/kg MD-fraction by oral administration for 10 days. After day 20, solid tumors were extirpated and weighed to determine the tumor growth inhibition ratio. Tumor regression of 75-85-percent was observed. Treatment with the MD-fraction increased the activities of natural killer cells, cytotoxic T cells, macrophages, and delayed-type hypersensitivity T cells by 1.23-2.5 times. The production of interleukin-1 (IL-1) from macrophages and of interleukin-2 (IL-2) from helper T cells was potentiated by 1.7-3.4 times. From these results the conclusion may be drawn that the immune-competent cell abilities to inhibit tumor growth were enhanced by MD-fraction. (1,2)
